Treating Pleural and Peritoneal Mesothelioma with LMB-100 and SEL-110
Type: Pleural, Peritoneal Mesothelioma
The National Cancer Institute (NCI) is researching how the drug combination of LMB-100 and SEL-110 will help combat pleural and peritoneal mesothelioma. Researchers at NCI will also be studying how safe the drug combination is and how well mesothelioma patients respond to the treatment.
Treating Mesothelioma Patients with LMB-100 and SEL-110
A phase 1 clinical trial is recruiting individuals with advanced mesothelioma. Researchers anticipate that combining the drugs LMB-100 and SEL-110 will help combat this asbestos-related disease.
The goal of this clinical trial is to test how safe the drugs LMB-100 and SEL-110 are. Researchers will also be evaluating how well patients can tolerate this drug combination.
LMB-100 – is a man-made protein. It works by targeting mesothelin that is on the surface of mesothelioma tumors. When LMB-100 combines with mesothelin it is capable of attacking and killing cancer cells.
SEL-110 – is an anti-drug antibody. SEL-110 is believed to help prevent antibodies from being created in the immune system.
Sometimes the performance of LMB-100 can be prohibited by antibodies that are created by the body. Researchers anticipate that if they treat mesothelioma patients with LMB-100 and SEL-110, that it will prevent the formation of these antibodies and allow LMB-100 to do its job.
There is great hope that the drug pairing will be a successful method of combating mesothelioma.
Get Help Enrolling in This Trial
Reasons to get involved in this trial include:
- Receive proven life-extending treatment
- Researchers believe that LMB-100 and SEL-110 will work together to attack and kill cancer cells
- Dr. Raffit Hassan, the lead investigator of the study, has years of experience treating and researching mesothelioma
Screening Pleural and Peritoneal Mesothelioma Candidates
The study is currently recruiting pleural and peritoneal mesothelioma patients. To be a successful candidate for the trial, an individual must have participated in at least one cycle of chemotherapy.
Candidates will undergo a series of screenings for the trial. Participants will be asked about their medical history and they will be given a physical exam. Patients must also be willing to provide a sample of their tumor tissue.
Additional tests will be given to ensure the safety of all of the trial’s participants.
Enrollees will also experience:
- Blood and urine tests
- Heart function tests
- Scans of their chest, abdomen, and pelvis
- Positron emission tomography (FDG-PET) scan
A patient must be willing to repeat some of the tests while they are receiving treatment in the trial. They must also be available to complete some of the exams after they’ve completed their final treatment session.
What to Expect: Getting Treated With LMB-100 and SEL-110
The trial will be conducted in 21-day cycles. Participants will receive both LMB-100 and SEL-110 by an IV infusion. Each patient will be given the drug combination for up to 4 treatment cycles.
A participant will be given LMB-100 for approximately 30 minutes on days 1, 3, and 5 of each cycle. For about an hour on day 1 of every treatment cycle, a patient will receive the drug SEL-110.
Is This Clinical Trial for You?
Lead investigator of the study is mesothelioma specialist, Dr. Raffit Hassan. Dr. Hassan plays an active role in improving treatment for mesothelioma patients. His research includes using mesothelin as a target for cancer therapy and immunotherapy.
This study is sponsored by the National Cancer Institute and is looking for participants to enroll at their National Institutes of Health Clinical Center in Bethesda, Maryland. The clinical trial plans to accept about 40 participants.
To guarantee the safety of participants, there are some criteria that a patient must meet.
- Confirmed diagnosis of peritoneal or pleural mesothelioma
- Mesothelioma cell type is either epithelial or biphasic
- At least 1 round of first-line chemotherapy
- Not considered a surgical candidate
For more information about this trial or any other recruiting clinical trial, please contact Jenna Campagna. You can reach her at 888-385-2024 extension 102 or by emailing email@example.com.